Primary CD8+ T-cell Response to Soluble Ovalbumin is Improved by Chloroquine Treatment in Vivo

Overview

Journal Clin Vaccine Immunol

Publisher American Society for Microbiology

Specialties Allergy & Immunology
Pathology

Date 2008 Aug 30

PMID 18753338

Citations 22

Authors

Bruno Garulli

Maria G Stillitano

Vincenzo Barnaba

Maria R Castrucci

Affiliations

Soon will be listed here.

Abstract

The efficiency of cross-presentation of exogenous antigens by dendritic cells (DCs) would seem to be related to the level of antigen escape from massive degradation mediated by lysosomal proteases in an acidic environment. Here, we demonstrate that a short course of treatment with chloroquine in mice during primary immunization with soluble antigens improved the cross-priming of naïve CD8(+) T lymphocytes in vivo. More specifically, priming of chloroquine-treated mice with soluble ovalbumin (OVA), OVA associated with alum, or OVA pulsed on DCs was more effective in inducing OVA-specific CD8(+) T lymphocytes than was priming of untreated mice. We conclude that chloroquine treatment improves the cross-presentation capacity of DCs and thus the size of effector and memory CD8(+) T cells during vaccination.

Citing Articles

Rationally designed catalytic nanoplatform for enhanced chemoimmunotherapy via deploying endogenous plus exogenous copper and remodeling tumor microenvironment.

Sun D, Yu L, Wang G, Xu Y, Wang P, Wang N J Nanobiotechnology. 2024; 22(1):551.

PMID: 39252079 PMC: 11385821. DOI: 10.1186/s12951-024-02696-x.

Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines.

Borrajo M, Lou G, Anthiya S, Lapuhs P, Alvarez D, Tobio A Drug Deliv Transl Res. 2024; 14(8):2046-2061.

PMID: 38811465 PMC: 11208213. DOI: 10.1007/s13346-024-01635-5.

Thermogenic T cells: a cell therapy for obesity?.

Beier U, Baker D, Baur J Am J Physiol Cell Physiol. 2022; 322(6):C1085-C1094.

PMID: 35476503 PMC: 9169824. DOI: 10.1152/ajpcell.00034.2022.

Immunology of COVID-19: Current State of the Science.

Vabret N, Britton G, Gruber C, Hegde S, Kim J, Kuksin M Immunity. 2020; 52(6):910-941.

PMID: 32505227 PMC: 7200337. DOI: 10.1016/j.immuni.2020.05.002.

Rethinking the role of hydroxychloroquine in the treatment of COVID-19.

Meyerowitz E, Vannier A, Friesen M, Schoenfeld S, Gelfand J, Callahan M FASEB J. 2020; 34(5):6027-6037.

PMID: 32350928 PMC: 7267640. DOI: 10.1096/fj.202000919.

References

Delamarre L, Holcombe H, Mellman I . Presentation of exogenous antigens on major histocompatibility complex (MHC) class I and MHC class II molecules is differentially regulated during dendritic cell maturation. J Exp Med. 2003; 198(1):111-22. PMC: 2196081. DOI: 10.1084/jem.20021542. View

Fox R . Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum. 1993; 23(2 Suppl 1):82-91. DOI: 10.1016/s0049-0172(10)80012-5. View

Wilson N, Behrens G, Lundie R, Smith C, Waithman J, Young L . Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol. 2006; 7(2):165-72. DOI: 10.1038/ni1300. View

den Haan J, Lehar S, Bevan M . CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med. 2000; 192(12):1685-96. PMC: 2213493. DOI: 10.1084/jem.192.12.1685. View

Bevan M . Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med. 1976; 143(5):1283-8. PMC: 2190184. DOI: 10.1084/jem.143.5.1283. View

Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, van Endert P, Amigorena S . ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature. 2003; 425(6956):397-402. DOI: 10.1038/nature01911. View

Gil-Torregrosa B, Lennon-Dumenil A, Kessler B, Guermonprez P, Ploegh H, Fruci D . Control of cross-presentation during dendritic cell maturation. Eur J Immunol. 2004; 34(2):398-407. DOI: 10.1002/eji.200324508. View

Lindblad E . Aluminium adjuvants--in retrospect and prospect. Vaccine. 2004; 22(27-28):3658-68. DOI: 10.1016/j.vaccine.2004.03.032. View

Wolkers M, Brouwenstijn N, Bakker A, Toebes M, Schumacher T . Antigen bias in T cell cross-priming. Science. 2004; 304(5675):1314-7. DOI: 10.1126/science.1096268. View

10.

Lyons A, Parish C . Determination of lymphocyte division by flow cytometry. J Immunol Methods. 1994; 171(1):131-7. DOI: 10.1016/0022-1759(94)90236-4. View

11.

Newman M, Wu J, Gardner B, Munroe K, Leombruno D, Recchia J . Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J Immunol. 1992; 148(8):2357-62. View

12.

Norbury C, Chambers B, Prescott A, Ljunggren H, Watts C . Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells. Eur J Immunol. 1997; 27(1):280-8. DOI: 10.1002/eji.1830270141. View

13.

Brossart P, Bevan M . Presentation of exogenous protein antigens on major histocompatibility complex class I molecules by dendritic cells: pathway of presentation and regulation by cytokines. Blood. 1997; 90(4):1594-9. PMC: 2778580. View

14.

Prato S, FLEMING J, Schmidt C, Corradin G, Lopez J . Cross-presentation of a human malaria CTL epitope is conformation dependent. Mol Immunol. 2006; 43(13):2031-6. DOI: 10.1016/j.molimm.2005.12.014. View

15.

Morrison L, Lukacher A, Braciale V, Fan D, Braciale T . Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones. J Exp Med. 1986; 163(4):903-21. PMC: 2188068. DOI: 10.1084/jem.163.4.903. View

16.

Schultz K, Bader S, Paquet J, Li W . Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease. Blood. 1995; 86(11):4344-52. View

17.

Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, Laplante A . Phagosomes are competent organelles for antigen cross-presentation. Nature. 2003; 425(6956):402-6. DOI: 10.1038/nature01912. View

18.

Collins D, Findlay K, Harding C . Processing of exogenous liposome-encapsulated antigens in vivo generates class I MHC-restricted T cell responses. J Immunol. 1992; 148(11):3336-41. View

19.

Ke Y, Li Y, Kapp J . Ovalbumin injected with complete Freund's adjuvant stimulates cytolytic responses. Eur J Immunol. 1995; 25(2):549-53. DOI: 10.1002/eji.1830250237. View

20.

ZIEGLER H, UNANUE E . Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci U S A. 1982; 79(1):175-8. PMC: 345685. DOI: 10.1073/pnas.79.1.175. View